دورية أكاديمية
أعرض في EDS

Longitudinal follow-up of metformin treatment in Fragile X Syndrome.

التفاصيل البيبلوغرافية
العنوان: Longitudinal follow-up of metformin treatment in Fragile X Syndrome.
المؤلفون: Seng P; MIND Institute, University of California Davis Health System, Sacramento, CA, United States., Montanaro FAM; Child and Adolescent Neuropsychiatry Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.; Department of Education, Psychology, Communication, University of Bari Aldo Moro, Bari, Italy., Biag HMB; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, United States., Salcedo-Arellano MJ; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, United States., Kim K; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, CA, United States.; Integrative Genetics and Genomics Graduate Group, University of California Davis, Davis, CA, United States., Ponzini MD; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, CA, United States., Tassone F; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA, United States., Schneider A; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, United States., Abbeduto L; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, United States., Thurman AJ; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, United States., Hessl D; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, United States., Bolduc FV; Department of Pediatrics, Department of Medical Genetics, Women and Children Health Research Institute, University of Alberta, Edmonton, AB, Canada., Jacquemont S; CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada.; Department of Pediatrics, University of Montreal, Montreal, QC, Canada., Lippé S; CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada.; Department of Psychology, Université de Montréal, Montreal, QC, Canada., Hagerman RJ; MIND Institute, University of California Davis Health System, Sacramento, CA, United States.; Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, CA, United States.
المصدر: Frontiers in psychology [Front Psychol] 2024 Jun 13; Vol. 15, pp. 1305597. Date of Electronic Publication: 2024 Jun 13 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101550902 Publication Model: eCollection Cited Medium: Print ISSN: 1664-1078 (Print) Linking ISSN: 16641078 NLM ISO Abbreviation: Front Psychol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Pully, Switzerland : Frontiers Research Foundation
مستخلص: Introduction: Metformin has been used as a targeted treatment to potentially improve cognition and slow the typical IQ decline that occurs during development among individuals with fragile X syndrome (FXS). In this follow-up study, we are following the trajectory of IQ and adaptive behavior changes over 1 to 3 years in individuals with FXS who are clinically treated with metformin in an open label trial.
Method: Individuals with FXS ages 6 to 25 years (mean 13.15 ± 5.50) and nonverbal IQ mean 57.69 (±15.46) were treated for 1-3 years (1.88 ± 0.63). They all had a baseline IQ test using the Leiter-III non-verbal cognitive assessment and the Vineland-III adaptive behavior assessment before the start of metformin. Repeat Leiter-III and Vineland-III were completed after at least 1 year of metformin (500-1,000 mg/dose given twice a day).
Result: There were no significant changes in non-verbal IQ or in the adaptive behavior measurements at FDR < 0.05. The findings thus far indicate that both IQ and adaptive behavior are stable over time, and we did not see a significant decline in either measure.
Conclusion: Overall, the small sample size and short follow-up duration limit the interpretation of the effects of metformin on cognitive development and adaptive functioning. There is individual variability but overall for the group there was no significant decline in IQ or adaptive behavior.
Competing Interests: RH has received funding from Zynerba Pharmaceuticals and Tetra pharmaceuticals for treatment studies involving patients with FXS. FT has received funding from Zynerba Pharmaceuticals for a study in FXS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor DP declared a past co-authorship with the authors MS-A, KK, FT, AS, DH, and RH.
(Copyright © 2024 Seng, Montanaro, Biag, Salcedo-Arellano, Kim, Ponzini, Tassone, Schneider, Abbeduto, Thurman, Hessl, Bolduc, Jacquemont, Lippé and Hagerman.)
References: JAMA Psychiatry. 2016 Sep 1;73(9):928-37. (PMID: 27556593)
Curr Genomics. 2011 May;12(3):216-24. (PMID: 22043169)
Nat Med. 2017 Jun;23(6):674-677. (PMID: 28504725)
J Abnorm Child Psychol. 2008 Aug;36(6):927-39. (PMID: 18347972)
Am J Intellect Dev Disabil. 2015 Sep;120(5):412-32. (PMID: 26322389)
J Am Acad Child Adolesc Psychiatry. 1990 Mar;29(2):214-9. (PMID: 2324062)
Intractable Rare Dis Res. 2016 Nov;5(4):255-261. (PMID: 27904820)
Am J Dis Child. 1985 Jul;139(7):674-8. (PMID: 4014089)
Am J Hum Genet. 2009 Oct;85(4):503-14. (PMID: 19804849)
Annu Rev Med. 2019 Jan 27;70:167-181. (PMID: 30365357)
Mol Genet Genomic Med. 2019 Jul;7(7):e00745. (PMID: 31104364)
J Mol Diagn. 2008 Jan;10(1):43-9. (PMID: 18165273)
Clin Genet. 2018 Feb;93(2):216-222. (PMID: 28436599)
Am J Med Genet A. 2007 Oct 15;143A(20):2478-89. (PMID: 17853466)
Mol Psychiatry. 2017 Aug;22(8):1140-1148. (PMID: 27090306)
Pediatrics. 2009 Jan;123(1):378-90. (PMID: 19117905)
J Intellect Disabil Res. 2015 Jul;59(7):613-21. (PMID: 25160119)
Am J Med Genet. 1996 Aug 9;64(2):350-5. (PMID: 8844079)
Am J Ment Retard. 1987 Nov;92(3):272-8. (PMID: 3426837)
Brain Sci. 2019 Jan 23;9(2):. (PMID: 30678024)
J Am Acad Child Adolesc Psychiatry. 1989 May;28(3):422-6. (PMID: 2786867)
Pediatrics. 2014 Aug;134(2):315-24. (PMID: 25070318)
Am J Med Genet. 1989 Aug;33(4):513-8. (PMID: 2596514)
J Child Neurol. 2022 Oct;37(10-11):797-812. (PMID: 35791522)
J Autism Dev Disord. 2002 Apr;32(2):107-14. (PMID: 12058838)
Diabetes Care. 2009 Sep;32(9):1743-5. (PMID: 19502540)
Am J Med Genet. 1999 Apr 2;83(4):308-12. (PMID: 10208167)
Wiley Interdiscip Rev Cogn Sci. 2014 Jul;5(4):501-508. (PMID: 25485036)
J Dev Behav Pediatr. 2016 Oct;37(8):619-28. (PMID: 27560971)
Am J Psychiatry. 2006 Dec;163(12):2072-9. (PMID: 17151157)
Am J Med Genet. 1994 Jul 15;51(4):353-7. (PMID: 7942998)
Mol Genet Genomic Med. 2019 Nov;7(11):e956. (PMID: 31520524)
J Neurodev Disord. 2023 Jan 9;15(1):1. (PMID: 36624400)
Nat Rev Neurosci. 2021 Apr;22(4):209-222. (PMID: 33608673)
Nat Rev Dis Primers. 2017 Sep 29;3:17065. (PMID: 28960184)
Clin Chem. 2010 Mar;56(3):399-408. (PMID: 20056738)
Front Genet. 2014 Jul 17;5:226. (PMID: 25101111)
Gac Med Mex. 2020;156(1):60-66. (PMID: 32026885)
فهرسة مساهمة: Keywords: IQ; adaptive behavior; fragile X syndrome; longitudinal follow-up; metformin; treatment
تواريخ الأحداث: Date Created: 20240628 Latest Revision: 20240710
رمز التحديث: 20240710
مُعرف محوري في PubMed: PMC11210589
DOI: 10.3389/fpsyg.2024.1305597
PMID: 38939222
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-1078
DOI:10.3389/fpsyg.2024.1305597